文献速递心脑血管急症

极低危急性胸痛患者可否不做肌钙蛋白检测

Identification of very low-risk acute chest pain patients without troponin testing.
PubMed 文献 · Emerg Med J · 2020-08-04
一句话结论HEAR评分0或1分的急性胸痛患者30天主要不良心脏事件发生率0.9%,肌钙蛋白检测未改善识别,作者认为该组可能无需肌钙蛋白检测即可达到漏诊率<1%。

该研究为HEART Pathway实施研究的二次分析,纳入美国3个中心2014年11月至2016年1月成人胸痛患者,由接诊医生完成HEAR评分及0和3小时系列肌钙蛋白检测。4979例完成HEAR评估者中9.0%(447/4979)HEAR评分<1分,该组30天主要不良心脏事件(死亡、心肌梗死、冠状动脉血运重建的复合终点)发生率为0.9%(4/447;95%CI 0.2%~2.3%),包括2例死亡、2例心肌梗死、0例血运重建。HEAR<1分对主要不良心脏事件的敏感度为97.8%(95%CI 94.5%~99.4%),阴性预测值为99.1%(95%CI 97.7%~99.8%),肌钙蛋白检测未改善上述指标;肌钙蛋白检测正确重分类2例发生主要不良心脏事件的患者,同时在7例未发生主要不良心脏事件的患者中升高,净重分类改善指数为0.9%(95%CI -0.7%~2.4%)。作者认为HEAR评分0和1分代表极低危组,可能无需肌钙蛋白检测即可达到主要不良心脏事件漏诊率<1%。

要点

  • HEAR评分<1分(即0或1分)的急性胸痛患者30天主要不良心脏事件发生率为0.9%(4/447;95%CI 0.2%~2.3%)。
  • HEAR<1分对主要不良心脏事件的敏感度为97.8%(95%CI 94.5%~99.4%),阴性预测值为99.1%(95%CI 97.7%~99.8%),肌钙蛋白检测未改善。
  • HEAR<1分患者中肌钙蛋白检测的净重分类改善指数为0.9%(95%CI -0.7%~2.4%),未达统计学显著。
  • 作者认为HEAR评分0和1分的极低危组可能无需肌钙蛋白检测即可达到主要不良心脏事件漏诊率<1%。

适用人群与场景

  • 美国3个中心就诊的成人急性胸痛患者,由接诊医生完成HEART Pathway风险评估(HEAR评分及0和3小时系列肌钙蛋白检测)。

诊断标准与关键阈值

  • HEAR评分<1分定义为0分或1分,由病史、心电图、年龄、危险因素组成。
  • 主要不良心脏事件定义为30天内死亡、心肌梗死和冠状动脉血运重建的复合终点。

研究设计与关键结果

  • 研究类型为HEART Pathway实施研究的二次分析,纳入4979例完成HEAR评估的成人胸痛患者,HEAR评分<1分者占9.0%(447/4979)。
  • HEAR<1分患者30天主要不良心脏事件发生率为0.9%(4/447;95%CI 0.2%~2.3%),包括2例死亡、2例心肌梗死、0例血运重建。
  • HEAR<1分对主要不良心脏事件的敏感度为97.8%(95%CI 94.5%~99.4%),阴性预测值为99.1%(95%CI 97.7%~99.8%),肌钙蛋白检测未改善。
  • 肌钙蛋白检测正确重分类2例发生主要不良心脏事件的患者,在7例未发生主要不良心脏事件的患者中升高,净重分类改善指数为0.9%(95%CI -0.7%~2.4%)。

证据类型、等级与局限

  • 证据类型为对HEART Pathway实施研究的二次分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为HEAR评分0和1分的极低危组可能无需肌钙蛋白检测即可达到主要不良心脏事件漏诊率<1%。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The HEART Pathway combines a History ECG Age Risk factor (HEAR) score and serial troponins to risk stratify patients with acute chest pain. However, it is unclear whether patients with HEAR scores of <1 require troponin testing. The objective of this study is to measure the major adverse cardiac event (MACE) rate among patients with <1 HEAR scores and determine whether serial troponin testing is needed to achieve a miss rate <1%.

METHODS: A secondary analysis of the HEART Pathway Implementation Study was conducted. HEART Pathway risk assessments (HEAR scores and serial troponin testing at 0 and 3 hours) were completed by the providers on adult patients with chest pain from three US sites between November 2014 and January 2016. MACE (composite of death, myocardial infarction (MI) and coronary revascularisation) at 30 days was determined. The proportion of patients with HEAR scores of <1 diagnosed with MACE within 30 days was calculated. The impact of troponin testing on patients with HEAR scores of <1 was determined using Net Reclassification Improvement Index (NRI).

RESULTS: Providers completed HEAR assessments on 4979 patients and HEAR scores<1 occurred in 9.0% (447/4979) of patients. Among these patients, MACE at 30 days occurred in 0.9% (4/447; 95% CI 0.2% to 2.3%) with two deaths, two MIs and 0 revascularisations. The sensitivity and negative predictive value for MACE in the HEAR <1 was 97.8% (95%CI 94.5% to 99.4%) and 99.1% (95% CI 97.7% to 99.8%), respectively, and were not improved by troponin testing. Troponin testing in patients with HEAR <1 correctly reclassified two patients diagnosed with MACE, and was elevated among seven patients without MACE yielding an NRI of 0.9% (95%CI -0.7 to 2.4%).

CONCLUSION: These data suggest that patients with HEAR scores of 0 and 1 represent a very low-risk group that may not require troponin testing to achieve a missed MACE rate <1%. Trial registration number NCT02056964.

来源:Emerg Med J,查看原文。版权归原作者所有。

参考来源

  1. Smith LM, Ashburn NP, Snavely AC, et al. Identification of very low-risk acute chest pain patients without troponin testing. Emerg Med J. 2020. PMID: 32753395. doi:10.1136/emermed-2020-209698

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。